Optimizing the use of vilobelimab for the treatment of COVID-19

Expert Opinion on Biological Therapy, Journal Year: 2023, Volume and Issue: 23(9), P. 877 - 881

Published: July 8, 2023

Introduction On 4 April 2023i4 2023, the United States Food and Drug Administration issued an emergency use authorization for of vilobelimab (GohibicTM) treatment COVID-19 in hospitalized adults when initiated within 48 hours receiving invasive mechanical ventilation or extracorporeal membrane oxygenation.Areas Covered Vilobelimab is a human-mouse chimeric IgG4 kappa antibody that targets human complement component 5a, part immune system thought to play important role systemic inflammation due SARS-CoV-2 infection leads disease progression.Expert Opinion A pragmatic, adaptive, randomized, multicenter phase II/III study evaluating severe found patients usual care who were treated with had lower risk death by day 28 60 compared those placebo. This manuscript explores what known about how this may be used future treat COVID-19.

Language: Английский

---

Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 31, 2022

Background Since the global epidemic of coronavirus disease 2019 (COVID-19), a large number immunological studies related to COVID-19 have been published in various immunology journals. However, results from these were discrete, and no study summarized important information about released by This aimed comprehensively summarize knowledge structure research hotspots major journals through bibliometrics. Methods Publications on obtained Web Science Core Collection. CiteSpace, VOSviewer, R-bibliometrix used for bibliometric visual analysis. Results 1,331 5,000 publications 10 with high impact factors most papers included, respectively. The USA, China, England, Italy made significant contributions papers. University College London, National Institute Allergy Infectious Diseases, Harvard Medical School, California San Diego, Pennsylvania played central role international cooperation field COVID-19. Yuen Kwok Yung was author terms citations, H-index. CLINICAL INFECTIOUS DISEASES FRONTIERS IN IMMUNOLOGY essential These mostly focused following topics: “Delta/Omicron variants”, “cytokine storm”, “neutralization/neutralizing antibody”, “T cell”, “BNT162b2”, “mRNA vaccine”, “vaccine effectiveness/safety”, “long COVID”. Conclusion systematically uncovered holistic picture current perspective bibliometrics, which will provide reference future this field.

Language: Английский

---

Heme Interactions as Regulators of the Alternative Pathway Complement Responses and Implications for Heme-Associated Pathologies

Current Issues in Molecular Biology, Journal Year: 2023, Volume and Issue: 45(6), P. 5198 - 5214

Published: June 16, 2023

Heme (Fe2+-protoporphyrin IX) is a pigment of life, and as prosthetic group in several hemoproteins, it contributes to diverse critical cellular processes. While its intracellular levels are tightly regulated by networks heme-binding proteins (HeBPs), labile heme can be hazardous through oxidative In blood plasma, scavenged hemopexin (HPX), albumin other proteins, while also interacts directly with complement components C1q, C3 factor I. These direct interactions block the classical pathway (CP) distort alternative (AP). Errors or flaws metabolism, causing uncontrolled stress, lead severe hematological disorders. Direct extracellular (APCCs) may implicated molecularly conditions at sites abnormal cell damage vascular injury. such disorders, deregulated AP could associated heme-mediated disruption physiological heparan sulphate–CFH coat stressed cells induction local hemostatic responses. Within this conceptual frame, computational evaluation HBMs (heme-binding motifs) aimed determine how APCCs whether these affected genetic variation within putative HBMs. Combined analysis database mining identified all 16 examined, 10 exhibiting disease-associated (SNPs) and/or epigenetic (PTMs). Overall, article indicates that among pleiotropic roles reviewed, induce differential AP-mediated hemostasis-driven pathologies certain individuals.

Language: Английский

---

Is post-COVID osteonecrosis of jaw (PCONJ) Masquerading as osteomyelitis ? A largest unicentric report of 13 cases

Advances in Oral and Maxillofacial Surgery, Journal Year: 2023, Volume and Issue: 11, P. 100435 - 100435

Published: June 1, 2023

The purpose of this study was to ascertain the correlation between COVID-19 infection and jaw osteonecrosis, along with identification risk factors that could be associated development condition. Another aim our is establish whether maxillofacial osteonecrosis an early or late complication seen in patients. This a retrospective conducted over period two years. Case records patients history severe COVID steroid treatment who later developed were evaluated. 13 age range from 8 years 70 identified. Osteonecrosis as 21 months after COVID-19. majority cases involved maxilla, one case bi-jaw involvement, presented isolated mandibular involvement. 6 diabetic 11 gave provocative dental like extraction. A triad post-COVID coagulopathy, administration, may contribute which without pre-existing systemic illness present

Language: Английский

---

Missense Variants of von Willebrand Factor in the Background of COVID-19 Associated Coagulopathy

Genes, Journal Year: 2023, Volume and Issue: 14(3), P. 617 - 617

Published: Feb. 28, 2023

COVID-19 associated coagulopathy (CAC), characterized by endothelial dysfunction and hypercoagulability, evokes pulmonary immunothrombosis in advanced cases. Elevated von Willebrand factor (vWF) levels reduced activities of the ADAMTS13 protease are common CAC. Here, we aimed to determine whether genetic variants these proteins might be with severity hemostatic parameters. A set single nucleotide polymorphisms (SNPs) vWF (rs216311, rs216321, rs1063856, rs1800378, rs1800383) genes (rs2301612, rs28729234, rs34024143) were genotyped 72 patients. Cross-sectional cohort analysis revealed no association any polymorphism disease severity. On other hand, variance (ANOVA) uncovered associations following clinical parameters: (1) rs216311 T allele enhanced INR (international normalized ratio); (2) rs1800383 C elevated fibrinogen levels; (3) rs1063856 increased red blood cell count, hemoglobin, creatinine levels. No could observed between phenotypic data gene. Importantly, silico protein conformational predicted that missense would display global alterations, which affect stability plasma vWF. Our results imply modulate thrombotic risk COVID-19.

Language: Английский

---